[Benign monomelic amyotrophy].

T. Hamano,T. Mutoh,M. Hirayama,M. Kuriyama

Abstract:

What problem does this paper attempt to address?

Quality of Life Following Receipt of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer

Shoshana M Rosenberg,Anne O'Neill,Karen Sepucha,Kathy D Miller,Chau T Dang,Donald W Northfelt,George W Sledge,Bryan P Schneider,Ann H Partridge

DOI: https://doi.org/10.1001/jamanetworkopen.2022.0254

2022-02-01

Abstract:Importance: Breast cancer treatment can impact not only short-term health but may also affect longer-term quality of life (QOL). Objective: To describe and evaluate factors associated with diminished QOL following completion of active treatment. Design, setting, and participants: This was a secondary analysis of a randomized clinical trial included patients with lymph node-positive or high-risk lymph node-negative breast cancer who had undergone definitive surgery and were enrolled in ECOG-ACRIN E5103, a multisite phase 3 trial. A survey was administered 18 months after enrollment to patients enrolled between January and June 2010. Final analysis of the data took place from March to December 2021. Interventions: Patients received adjuvant doxorubicin, cyclophosphamide, and paclitaxel with either bevacizumab or placebo. Main outcomes and measures: QOL and health status assessed with the EuroQol 5-Dimension 3-Levels (EQ-5D-3L), EQ-visual analog scale (EQ-VAS), and the Functional Assessment of Cancer Therapy-Breast Cancer, with arm subscale (FACT-B+4). Groups were compared by Fisher exact test, Wilcoxon rank sum, or Kruskal-Wallis test. Multivariable linear regression was used to assess factors independently associated with FACT-B scores. Results: Data at 18 months were available from 455 of 519 patients (87.7%) enrolled in the trial. Median (range) age at enrollment was 52 (25-76) years. No differences in QOL (median [range] FACT-B scores: group A, 123 [67-146]; group B, 114 [54-148]; group C, 117 [42-148]; P = .23) or health status (median [range] EQ-5D-3L index scores: group A, 0.83 [0.28-1.00]; group B, 0.83 [0.20-1.00]; group C, 0.83 [0.17-1.00], P = .80; median EQ-VAS: group A, 85 [20-100]; group B, 85 [0-100]; group C, 85 [0-100]; P = .79) were observed across treatment groups; results for subsequent analyses were therefore reported irrespective of primary treatment. Overall, half of patients (258 of 444 [58%]) reported at least some pain or discomfort; 170 (38%) reported symptoms of anxiety or depression. In multivariable analyses, mastectomy with radiation (vs breast conserving surgery) and Asian, Black, or American Indian or Alaska Native race (vs White race) were associated with lower QOL (mastectomy with radiation: coefficient: -5.5; 95% CI, -10.1 to -0.9; Asian, Black, or American Indian or Alaska Native race: coefficient: -7.3; 95% CI, -13.2, -1.4). Conclusions and relevance: In this study, the addition of bevacizumab to chemotherapy was not negatively associated with QOL at 18 months. A substantial proportion of participants reported problems related to pain or discomfort and anxiety or depression, demonstrating persistent consequences for physical and psychosocial well-being in this heavily treated population. Many problems reported are amenable to intervention, underscoring the need for timely referral to supportive resources, especially for women of color and those who have more extensive local therapy. Trial registration: ClinicalTrials.gov Identifier: NCT00433511.
Efficacy and Toxicity of Addition of Bevacizumab to Chemotherapy in Patients with Metastatic Colorectal Cancer.

Wen-Cong Ruan,Yue-Ping Che,Li Ding,Hai-Feng Li

DOI: https://doi.org/10.2174/1386207322666190119162352

2019-01-01

Combinatorial Chemistry & High Throughput Screening

Abstract:Background: Pre-treated patients with first-line treatment can be offered a second treatment with the aim of improving their poor clinical prognosis. The therapy of metastatic colorectal cancer (CRC) patients who did not respond to first-line therapy has limited treatment options. Recently, many studies have paid much attention to the efficacy of bevacizumab as an adjuvant treatment for metastatic colorectal cancer. Objectives: We aimed to evaluate the efficacy and toxicity of bevacizumab plus chemotherapy compared with bevacizumab-naive based chemotherapy as second-line treatment in people with metastatic CRC. Methods: Electronic databases were searched for eligible studies updated to March 2018. Randomized-controlled trials comparing addition of bevacizumab to chemotherapy without bevacizumab in MCRC patients were included, of which, the main interesting results were the efficacy and safety profiles of the addition of bevacizumab in patients with MCRC as second-line therapy. Result: Five trials were eligible in the meta-analysis. Patients who received the combined bevacizumab and chemotherapy treatment in MCRC as second-line therapy showed a longer overall survival (OS) (OR=0.80,95% CI=0.72-0.89, P<0.0001) and progression-free survival (PFS) (OR=0.69,95% CI=0.61-0.77, P<0.00001). In addition, there was no significant difference in objective response rate (ORR) (RR=1.36,95% CI=0.82-2.24, P=0.23) or severe adverse event (SAE) (RR=1.02,95% CI=0.88-1.19, P=0.78) between bevacizumab-based chemotherapy and bevacizumab-naive based chemotherapy. Conclusion: Our results suggest that the addition of bevacizumab to the chemotherapy therapy could be an efficient and safe treatment option for patients with metastatic colorectal cancer as second-line therapy and without increasing the risk of an adverse event.
Real-world study of bevacizumab treatment in patients with ovarian cancer: a Chinese single-institution study of 155 patients

Nan Zhang,Hong Zheng,Yunong Gao,Tong Shu,Hongguo Wang

DOI: https://doi.org/10.1186/s12905-023-02329-9

2023-04-13

BMC Women s Health

Abstract:Objective: The purpose of this study was to retrospectively assess the pattern, compliance, efficacy and safety of bevacizumab in Chinese ovarian cancer patients. Methods: We reviewed the clinicopathological data of patients with histologically confirmed epithelial ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma, who were diagnosed and treated at the Department of Gynecologic Oncology of Peking University Cancer Hospital between May 2012 and January 2022. Results: A total of 155 patients were eventually enrolled in this study, with 77 as first-line chemotherapy (FL) and 78 as recurrence therapy (RT) among which 37 patients were platinum sensitive and 41 were platinum resistant. Among the 77 patients in the FL group, 35 received bevacizumab during neoadjuvant chemotherapy (NACT) alone (NT), 23 received bevacizumab during both neoadjuvant and first-line chemotherapy (NT + FL) and 19 received bevacizumab during first-line chemotherapy alone (FLA). Among the 43 patients of NT and NT + FL groups undergoing interval debulking surgery (IDS), 38(88.4%) patients achieved optimally debulking and 24 (55.8%) patients had no residual disease after IDS. The patients in the FL group had a median progression free survival (PFS) of 15(95%CI: 9.951-20.049) months, and the 12-month PFS was 61.7%. In the RT group, the overall response rate (ORR) was 53.8%. According to multivariate analysis, the patients' platinum sensitivity had a significant impact on the PFS in the RT group. 13(8.4%) patients discontinued bevacizumab due to toxicity. Seven patients were in the FL group while 4 patients were in the RT group. The most common adverse event associated with bevacizumab therapy was hypertension. Conclusion: Bevacizumab is effective and well-tolerated in the real world setting of ovarian cancer treatment. Adding bevacizumab to NACT is feasible and tolerable. Receiving the regimen containing bevacizumab in the last preoperative chemotherapy did not result in increased intraoperative bleeding of IDS. Platinum sensitivity is the most important factor affecting the effectiveness of bevacizumab in recurrent patients.
On increasing the number of pulmonary alveoli in rats by postnatal treatment with retinoic acid.

L. N. Blanco

DOI: https://doi.org/10.1152/AJPLUNG.1997.272.4.L792

1997-04-01

Abstract:Dexamethasone, a glucocorticosteroid hormone, inhibits the formation of alveoli; retinoids and glucocorticosteroid hormones can be mutually antagonistic. These observations led us to test the hypothesis that the administration of retinoic acid to postnatal rats would prevent the low alveolar number and the low body mass-specific gas-exchange surface area (Sa) produced by treatment with dexamethasone. We used serial lung sections to distinguish alveoli from alveolar ducts and stereological procedures that allow quantitation of alveoli uninfluenced by their size, shape, or distribution. Treatment with retinoic acid prevented the low number of alveoli and the low body mass-specific Sa caused by treatment with dexamethasone. In otherwise untreated rats, retinoic acid caused a 50% increase in the number of alveoli, but without an increase in Sa, suggesting the action of a regulatory mechanism to prevent unneeded Sa. These findings provide the first experimental support for the possibility that, in individuals with too few alveoli for adequate gas exchange, treatment with a pharmacological agent may provide preventative or remedial therapy.
Optimizing Outcomes: Bevacizumab with Carboplatin and Paclitaxel in 5110 Ovarian Cancer Patients—A Systematic Review and Meta-Analysis

Yu Jin Kim,Hee Min Lee,Ga Eun Lee,Jin Hui Yoo,Hwa Jeong Lee,Sandy Jeong Rhie

DOI: https://doi.org/10.3390/ph17081095

IF: 4.6

2024-08-23

Pharmaceuticals

Abstract:Background/Objectives: The study aimed to evaluate the efficacy and safety of incorporating bevacizumab into the combination therapy of carboplatin and paclitaxel for epithelial ovarian cancer and other clinical applications. Methods: A systematic review was conducted following PRISMA guidelines using keyword searches in PubMed, Embase, Cochrane Library, CINAHL, ClinicalTrials.gov, and ICTRP until February 2024. Randomized controlled trials (RCTs) comparing carboplatin and paclitaxel with and without bevacizumab in ovarian cancer patients were included. Efficacy outcomes were overall survival (OS) and progression-free survival (PFS), as described by hazard ratios (HRs). Safety outcomes were analyzed with risk ratios (RRs) for 16 adverse events. Results: Seven RCTs (n = 5110) were included. The combination with bevacizumab significantly improved PFS (HR: 0.73; 95% confidence interval: 0.58, 0.92; p = 0.008). The chemotherapy group receiving bevacizumab with carboplatin and paclitaxel showed a significantly higher incidence of hypertension, non-CNS bleeding, thromboembolic events, GI perforation, pain, and proteinuria. Conclusions: The combination of carboplatin, paclitaxel, and bevacizumab improves PFS compared to the regimen without bevacizumab, but it raises significant safety concerns. Clinical management should consider adverse event prevention by vigilantly monitoring blood pressure, signs and symptoms of bleeding, thromboembolism, GI perforation, and pain to balance the therapeutic benefits with the potential risks of this combination therapy.

pharmacology & pharmacy,chemistry, medicinal
Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian Cancer

Gordon Taylor Moffat,Weidong Kong,Helen J MacKay,Jacob McGee,Christopher M Booth,Josee-Lyne Ethier

DOI: https://doi.org/10.1016/j.ygyno.2024.01.027

Abstract:Objectives: The addition of bevacizumab to chemotherapy for platinum-resistant (PL-R) ovarian cancer (OC) improved progression-free (PFS) but not overall survival (OS) in clinical trials. We explored real-world outcomes in Ontario, Canada, and compared survival in the pre- and post-bevacizumab era. Methods: Administrative databases were utilized to identify all patients treated with bevacizumab for PL-R OC. Time on treatment (ToT) was used as surrogate for PFS. Median OS was determined using the Kaplan-Meier method. Factors associated with ToT/OS were identified using a Cox proportional hazard model. A before and after comparative effectiveness analysis was performed to determine mOS for patients treated pre- and post-bevacizumab approval. Results: From 2017 to 2019, 176 patients received bevacizumab. Median ToT was 3 months and OS was 11 months. Sixty-four percent received liposomal doxorubicin and 34% received paclitaxel. ToT (6 vs 3 months; HR 0.44; p < 0.0001) and OS (14 vs 9 months; HR 0.45; p = 0.0089) were longer with bevacizumab/paclitaxel. OS was not significantly different pre- and post-bevacizumab funding (8 vs 9 months; HR 1.01; 0.937). Median OS increased for those receiving paclitaxel (6 vs 11 months), but those in the post group were younger, more likely to have undergone primary surgery and had less co-morbidities. Conclusion: Real-world outcomes with bevacizumab in PL-R OC are inferior to those in the pivotal clinical trial. Survival has not significantly improved since funding became publicly available, indicating a substantial efficacy-effectiveness gap between trial and real-world outcomes. Median OS and ToT were significantly better when bevacizumab was given with paclitaxel.
Real-World Study of Neoadjuvant Chemotherapy with Bevacizumab in Patients with Ovarian Cancer: A Chinese single-institution study

Nan Zhang,Hong Zheng,Yunong Gao,Tong Shu,Hongguo Wang

DOI: https://doi.org/10.21203/rs.3.rs-2101680/v2

2022-01-01

Abstract:Abstract Background Bevacizumab was the first anti-angiogenic agent approved for the treatment of newly diagnosed and relapsed ovarian cancer. For patients with extensive tumor metastasis that is unsuitable for primary debulking surgery(PDS), platinum-based neoadjuvant chemotherapy(NACT) followed by interval debulking surgery(IDS) has become an important therapy strategy. The bevacizumab-containing regimens are also options for NACT and post-IDS chemotherapy. Although there have been many high-quality clinical trials of bevacizumab for ovarian cancer, real-world evidence is still necessary for clinical practice. Objective This study aimed to retrospectively assess the pattern, compliance, efficacy, and safety of bevacizumab as NACT in Chinese patients with ovarian cancer. Methods We reviewed the clinicopathological data of patients with histologically confirmed epithelial ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma, who were diagnosed and treated at the Department of Gynecologic Oncology of Peking University Cancer Hospital between May 2012 and January 2022. Results A total of 58 patients were ultimately enrolled in this study, with 35 receiving bevacizumab during NACT alone(NT) and 23 receiving bevacizumab during both neoadjuvant and first-line chemotherapy(NT + FL). Among the 43 patients in NT and NT + FL groups undergoing IDS, 38(88.4%) patients achieved optimal debulking and 24(55.8%) patients had no residual disease after IDS. All patients had a median PFS of 15 months (95%CI: 9.595–21.405), and the 12-month PFS was 60.2%. The median PFS of the NT and NT + FL groups were 13 months(95% CI: 9.738–16.262) and 20 months(95% CI:11.362–28.638), respectively. Nevertheless, there was no significant difference between the two groups(p = 0.113). According to multivariate analysis, patients treated with 15 mg/kg had a better PFS than those treated with ≤ 7.5 mg/kg(HR = 0.352, 95% CI: 0.143–0.864, P = 0.023). Hypertension was the most common adverse event associated with bevacizumab. A total of 5.2% (3/58) of patients discontinued bevacizumab due to toxicity. Conclusion Bevacizumab is effective and well-tolerated in the real-world setting of ovarian cancer NACT treatment. Receiving the regimen containing bevacizumab in the last preoperative chemotherapy did not result in increased intraoperative bleeding. Patients receiving the dosage of 15mg/kg may have better survival outcomes than those receiving the dosage of ≤ 7.5mg/kg.
Impact of Bevacizumab on Clinical Outcomes in Patients With Platinum-resistant Relapsed Ovarian Cancer

Aeran Seol,Se Ik Kim,Hee Yeun Yoon,Maria Lee,Hee Seung Kim,Hyun Hoon Chung,Noh Hyun Park,Yong Sang Song

DOI: https://doi.org/10.21873/invivo.13574

In Vivo

Abstract:Background/aim: Over the past several decades, new anti-cancer drugs have been developed for the treatment of epithelial ovarian cancer. The development of drugs has led to changes in improving the prognosis of ovarian cancer patients. One of these drugs, bevacizumab, is used for advanced or recurrent ovarian cancer. In this study, we aimed to evaluate survival improvement in patients with platinum-resistant relapsed epithelial ovarian cancer (PR-ROC) after introduction of bevacizumab in real world experience. Patients and methods: We retrospectively divided patients with PR-ROC into two groups: bevacizumab plus chemotherapy (BEV-CT group) and chemotherapy alone (CT group). Progression-free survival (PFS), the primary endpoint, between two groups was compared to evaluate whether survival outcomes were improved. In addition, overall survival (OS) was also compared. Results: A total of 154 patients were included in the study: 57 and 97 patients in the BEV-CT and CT groups, respectively. OS was significantly longer in the BEV-CT group than in the CT group. The use of bevacizumab was identified as a favorable prognostic factor for OS. In a subgroup analysis confined to second-line chemotherapy, PFS and OS were statistically different between groups. More patients in the CT group suffered hematologic adverse events of grade 3 or above than patients in the BEV-CT group. Conclusion: In a real-world clinical setting, introduction of bevacizumab led to improvement of OS in patients with PR-ROC with a tolerable toxicity.
Optimizing the Treatment of Bevacizumab As First-Line Therapy for Human Epidermal Growth Factor Receptor 2 (Her2)-Negative Advanced Breast Cancer: an Updated Meta-Analysis of Published Randomized Trials

Cunfu Li,Aizhai Xiang,Xianzhi Chen,Kai Yin,Jinsong Lu,Wenjin Yin

DOI: https://doi.org/10.2147/ott.s138600

IF: 4

2017-01-01

OncoTargets and Therapy

Abstract:Background: Manifold data have demonstrated that the addition of bevacizumab to chemotherapy improved progression-free survival (PFS), while few trials have revealed its significant overall survival (OS) benefit. Furthermore, it still remains suspended how to maximize the benefits of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative breast cancer. We sought to conduct a meta-analysis to assess the benefits of bevacizumab with chemotherapy and to identify the ideal chemotherapy partner of bevacizumab in the first-line setting for HER2-negative advanced breast cancer patients.Methods: Computerized and manual searches were performed to identify randomized clinical trials evaluating the efficacy of bevacizumab plus chemotherapy versus chemotherapy alone or bevacizumab with different chemotherapy regimens as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer patients. Risk ratios or odds ratios with their 95% CIs were used to estimate the association between multiple combinations of bevacizumab with chemotherapy and various clinical outcomes.Results: With 7 trials identified, this analysis included 3,984 eligible patients. The addition of bevacizumab to chemotherapy resulted in a statistically significant improvement in PFS (P=0.019) and objective response rate (ORR; P < 0.001) rather than in OS (P=0.783) when compared with chemotherapy alone. The greater benefits in PFS and ORR were achieved from bevacizumab plus taxane-based regimens compared with bevacizumab plus capecitabine-based regimens, while bevacizumab plus capecitabine had comparable OS with bevacizumab plus paclitaxel. Additionally, bevacizumab-based triplet therapy failed to improve the clinical outcomes when compared with doublet therapy.Conclusion: This meta-analysis reveals that the addition of bevacizumab to chemotherapy yielded PFS and ORR benefits in HER2-negative advanced breast cancer. Additional studies are still prompted to further optimize the first-line treatment of bevacizumab.
In vivo analysis reveals that the interdomain region of the yeast proliferating cell nuclear antigen is important for DNA replication and DNA repair.

N. Amin,C. Holm

IF: 4.402

1996-10-01

Genetics

Abstract:To identify the regions of the proliferating cell nuclear antigen (PCNA) that are important for function in vivo, we used random mutagenesis to isolate 10 cold-sensitive (Cs-) and 31 methyl methanesulfonate-sensitive (Mmss) mutations of the PCNA gene (POL30) in Saccharomyces cerevisiae. Unlike the Mmss mutations, the Cs- mutations are strikingly clustered in the interdomain region of the three-dimensional PCNA monomer structure. At the restrictive temperature, the Cs- pol30 mutants undergo a RAD9-dependent arrest as large-budded cells with a 2c DNA content. Defects in DNA synthesis are suggested by a significant delay in the progression of synchronized pol30 cells through S phase at the restrictive temperature. DNA repair defects are revealed by the observation that Cs- pol30 mutants are very sensitive to the alkylating agent MMS and mildly sensitive to ultraviolet radiation, although they are not sensitive to gamma radiation. Finally, analysis of the chromosomal DNA in pol30 cells by velocity sedimentation gradients shows that pol30 cells accumulate single-stranded DNA breaks at the restrictive temperature. Thus, our results show that PCNA plays an essential role in both DNA replication and DNA repair in vivo.
The efficacy of bevacizumab combined with platinum-containing chemotherapy in the treatment of advanced non-small cell lung cancer in China: a systematic review and meta-analysis of randomized clinical trials

Guangsu Han,Chenlu Li,Ping Yi

DOI: https://doi.org/10.3389/fphar.2024.1293039

IF: 5.6

2024-01-23

Frontiers in Pharmacology

Abstract:Background: Platinum-based dual-drug first-line chemotherapy is commonly employed in the treatment of patients with advanced non-small cell lung cancer (NSCLC), although its clinical efficacy is limited. Bevacizumab can antagonize vascular endothelial cell growth factor (VEGF), which inhibit tumor angiogenesis and prevent tumor invasion and development. However, a comprehensive meta-analysis evaluating the effectiveness and safety of combining bevacizumab with platinum-based chemotherapy in advanced NSCLC patients is lacking. Methods: Randomized controlled trials (RCTs) investigating the combination therapy of bevacizumab and platinum-based chemotherapy for treating advanced NSCLC were searched across six databases. Data on objective response rate (ORR), disease control rate (DCR), 1-year survival rate, 2-year survival rate, 3-year survival rate, VEGF levels, and side effects were synthesized. Relative risk degree (RR) along with 95% confidence interval (CI) was used as statistical analysis measures for binary outcomes while continuous variables were analyzed using mean difference (MD) along with 95% CI. Heterogeneity was evaluated by Chi-squared and I 2 tests. If there was heterogeneity, subgroup analysis was performed. Sensitivity analysis of the main outcome measures and assessment of publication bias were also performed. Results: According to our screening criteria, a total of Forty-nine RCTs were included, involving data from 4268 patients. The results of this analysis showed that compared with platinum-containing chemotherapy alone, bevacizumab combined with platinum-containing chemotherapy significantly improved ORR (RR [95% CI], 1.53 [1.44, 1.63], p < 0.00001), DCR (RR [95% CI], 1.24 [1.19, 1.29], p < 0.0001), 1-year survival rate (RR [95% CI], 1.34 [1.15, 1.57], p = 0.0003), 2-year survival rate (RR [95% CI], 2.16 [1.35, 3.43], p = 0.001), 3-year survival rate (RR [95% CI], 2.00 [1.21, 3.30], p = 0.007). In addition, bevacizumab with platinum-containing chemotherapy observably decreased the VEGF levels (RR [95% CI], −67.35 [−91.46, −43.25], p < 0.00001). Conclusion: Combination therapy involving bevacizumab demonstrated improved antitumor effects compared to chemotherapy alone in terms of ORR, DCR, 1-year survival rate, 2-year survival rate, 3-year survival rate, and VEGF levels without an increased incidence of adverse reactions. These analyses' results can provide clinicians guidance when selecting appropriate treatments for patients diagnosed with advanced non-small cell lung cancer.

pharmacology & pharmacy
Efficacy and Safety of Bevacizumab and Chemotherapy in Combination with Atezolizumab in Patients with Metastatic Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials

Chenfei Jiang,Dong Chen,Bin Sun,Rujia Wang

2023-01-01

Journal of biological regulators and homeostatic agents

Abstract:Background: Currently, the combination of atezolizumab, chemotherapy and bevacizumab is used to treat patients with metastatic colorectal cancer, but the effects on overall survival and safety are controversial. Therefore, this study systematically evaluated the efficacy and safety of bevacizumab, chemotherapy and atezolizumab in the treatment of this disease. Method: The English literature on treatment of colorectal cancer with bevacizumab and atezolizumab combined with chemotherapy from PubMed, Embase, Web of Science and the Cochrane Library 2023 was systematically searched until June. References were screened according to strictly defined inclusion and exclusion criteria. The included studies were evaluated for quality using Cochrane risk of bias Manual 5.3, and a meta-analysis was performed using Revman5.3. Included outcomes were progression-free survival (PFS), overall survival (OS), objective response rate (ORR), >3 Grade adverse events, and immune-related adverse events. Results: Three randomized controlled trials (RCTs) which included 791 colorectal cancer patients met the criteria. Meta-analysis results showed that bevacizumab and chemotherapy plus atezolizumab led to significantly greater PFS (hazard ratio (HR) = 0.75, 95% confidence interval (CI): 0.66 similar to 0.85, p < 0.00001) than bevacizumab and chemotherapy, with similar OS (HR = 0.97, 95% CI: 0.72 similar to 1.31, p = 0.84), ORR (odds ratio (OR) = 1.00, 95% CI: 0.67 similar to 1.49, p = 0.98), >3 Grade adverse events (OR = 1.37, 95% CI: 1.00 similar to 1.88, p = 0.05), and immune-related adverse events (OR = 3.47, 95% CI: 0.52 similar to 23.33, p = 0.20). Conclusions: Bevacizumab and chemotherapy combined with atezolizumab can prolong PFS in patients with metastatic colorectal cancer, and its safety is comparable to that of bevacizumab and chemotherapy. However, there is no significant improvement in OS and ORR of patients, more studies are needed to prove it.
Effectiveness and Safety of Adding Bevacizumab to Platinum-Based Chemotherapy as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis

Yi Liu,Hui-Min Li,Ran Wang

DOI: https://doi.org/10.3389/fmed.2021.616380

IF: 3.9

2021-06-30

Frontiers in Medicine

Abstract:Background and Objective: Previous studies have evaluated the efficacy (OS, overall survival; PFS, progression-free survival; ORR, objective response rate) and adverse events of bevacizumab combined with platinum-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer (NSCLC) compared with chemotherapy alone. However, the results were inconsistent. Methods: We conducted a comprehensive search of PubMed, EMBASE, and Cochrane Library for potentially eligible articles. The outcomes were evaluated in terms of risk ratio (RR) or hazard ratio (HR) and the associated 95% confidence intervals (CIs). Meta-analysis was performed using the Stata 12.0 software, and subgroup analyses were performed based on the treatment and bevacizumab dose. Results: Six randomized controlled trials with 2,465 patients were included in this meta-analysis. The results demonstrated that bevacizumab significantly increased OS (HR = 0.87, 95% CI 0.79–0.96), extended PFS (HR = 0.65, 95% CI 0.54–0.77), and increased ORR (ES = 0.40, 95% CI 0.31–0.48) when added to first-line platinum-based chemotherapy in patients with advanced NSCLC. Subgroup analyses showed that only the higher dose (15 mg/kg) of bevacizumab plus carboplatin–paclitaxel significantly extended the OS and PFS, but both 7.5 mg/kg and 15 mg/kg of bevacizumab improved ORR. However, both 7.5 mg/kg and 15 mg/kg of bevacizumab could only increase PFS and ORR, but not extend OS, when added to cisplatin–gemcitabine. Bevacizumab significantly increased the risk of grade ≥3 events of febrile neutropenia, haemorrhagic events, hypertension, leukopenia, neutropenia, and proteinuria. Conclusion: Bevacizumab significantly increases OS, PFS, and ORR when added to first-line platinum-based chemotherapy in patients with advanced NSCLC, with no new safety signals found. Moreover, bevacizumab (15 mg/kg) plus carboplatin–paclitaxel is a better alternative in increasing OS to carboplatin–paclitaxel and bevacizumab (7.5 mg/kg and 15 mg/kg) plus cisplatin–gemcitabine.

medicine, general & internal
Effect of low-dose bevacizumab on health-related quality of life in patients with recurrent high-grade glioma: A retrospective clinical study

Yonghong Liao,Xuexue Bai,Yiyao Cao,Maoying Zhang

DOI: https://doi.org/10.1016/j.jocn.2024.01.018

IF: 2.116

2024-01-26

Journal of Clinical Neuroscience

Abstract:Background We retrospectively analyzed the effects of low-dose bevacizumab (BEV) combined with temozolomide (TMZ) on health-related quality of life (HRQL) in patients with recurrent high-grade glioma (rHGG). Methods A total of 129 patients with rHGG were included in this study. Patients were divided into a combination group and TMZ group based on the treatment they received. The Quality of Life Questionnaire Core 30 (QLQ-C30) and EORTC Brain Cancer Module (QLQ-BN20) were used to evaluate HRQL in all patients before and after treatment. Categorical variables were compared using the chi-squared test. The data for all continuous variables were first tested for a normal distribution. If the data conformed to a normal distribution, a T test was used for comparison. If the data did not conform to a normal distribution, the rank-sum test was used. Results There were differences in PFS and PFS-6 between the BEV + TMZ and TMZ groups (P 0.05). The BEV + TMZ group performed better than the TMZ group in both the QLQ-C30 and QLQ-BN20. In addition, the KPS score was higher in the BEV + TMZ group than in the TMZ group. Steroid doses given were lower in the BEV + TMZ group than in the TMZ group (P < 0.05). Conclusions Low-dose BEV + TMZ can relieve the clinical symptoms of rHGG patients, reduce their steroid dose, improve HRQL, and prolong PFS, but does not bear any benefit on OS.

neurosciences,clinical neurology
Comparison of advanced ovarian cancer patients treated with or without bevacizumab in the US Community Oncology Clinics

Richard W DeClue,Elizabeth A Szamreta,Santosh Gautam,Maxine D Fisher,Matthew J Monberg

DOI: https://doi.org/10.2217/fon-2022-0955

Abstract:Aim: Real-world data on treatment patterns and outcomes of advanced ovarian cancer (OC) patients since bevacizumab approval in first-line (1L) OC treatment were assessed. Materials & methods: In this descriptive retrospective study using the ConcertAI Oncology Dataset, patient characteristics, treatment patterns and real-world progression-free survival (rwPFS) from start of 1L were evaluated among patients diagnosed with advanced OC between 2011-2020. Treatment data from structured sources were confirmed and/or supplemented by human review of unstructured data. Results: Median rwPFS for bevacizumab and non bevacizumab cohorts was 17.3 months (95% CI: 14.9, 20.4) and 15.7 months (95% CI: 12.3, 29.1), respectively. Patients with ≥10 doses during 1L had higher median rwPFS compared with patients receiving 3-9 doses. Conclusion: This real-world study suggests benefits of bevacizumab treatment in advanced OC were primarily experienced by patients who received ≥10 doses in 1L.
Abstract B056: The unconfounded effect of bevacizumab on advanced ovarian clear cell carcinoma: a systematic review, traditional meta-analysis, and network meta-analysis

Fisher Kuan-Ju Huang

DOI: https://doi.org/10.1158/1538-7445.ovarian23-b056

IF: 11.2

2024-03-05

Cancer Research

Abstract:Background Ovarian clear cell carcinoma (OCCC) accounts for 5-20% of all epithelail ovarian cancers, and is associated high recurrence rate and chemoresistance. There are some new therapies available in recent years, including bevacizumab, an anti-VEGF monoclonal antibody, and the poly ADP-ribose polymerase (PARP) inhibitors. Previous research and current support the use of both medication in OCCC. However, most of the studies reported results for all subtypes collectively in which OCCC only accounted for a small proportion of the study cohort. Besides, dislike the high-grade serous subtype, only around 10% of OCCC respond to poly ADP-ribose polymerase (PARP) inhibitor. In the subgroup analysis from ICON7, Bevacizumab had limited role in OCCC patients, in which OCCC of any stage were included. On the other hand, another 2 multi-center studies evaluated Bevacizumab as the front-line or salvage therapy revealed positive results. However, the results could be biased due to unadjusted confounders. Objective: To find the real effect of Bevacizumab on advanced stage OCCC. Materials and Methods: A systematic review via searching the Pubmed with "ovarian clear cell carcinoma" and "bevacizumab" was performed. Any comparative study met the inclusion criteria. The data were extracted, evaluated and classified by their combination of potential confounders. Primary data from National Taiwan University Hospital (NTUH) Database were collected and incorporated into the traditional meta-analysis, and the network meta-analysis. The potential confounders for analysis include "residual tumor", "FIGO stage", and "functional status". Results: There were 3 retrospective studies, including one single-center study from Japan (N=28), one multi-center study from Japan (N=145), and one multi-center study from Korea (N=138). There were 64 patients identified from NTUH database between 2011 and 2020. By traditional meta-analysis, it revealed Bevacizumab is associated with improved progression-free survival (HR 0.62, 95% C.I. 0.44 - 0.87, common effect model, I2= 50%). After adjusted for confonders and analyzed by network meta-analysis, however, only "no residual tumor" is associated with improved progression-free survival (HR 0.37, 95% C.I. 0.14 - 0.97). The role of Bevacizumab on OCCC is limited (HR 1.20, 95% C.I. 0.51 - 2.83). Conclusion: By adjusting for possible confounders in published studies, it reveals that Bevacizumab may not improve progression-free survival in advanced-stage OCCC from a network meta-analysis. Citation Format: Fisher Kuan-Ju Huang. The unconfounded effect of bevacizumab on advanced ovarian clear cell carcinoma: a systematic review, traditional meta-analysis, and network meta-analysis [abstract]. In: Proceedings of the AACR Special Conference on Ovarian Cancer; 2023 Oct 5-7; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_2) nr B056.

oncology
Analysis of progression-free and overall survival in ovarian cancer: Bevacizumab treatment outcomes using historical cohort

I Conic,B Nedovic,R Zivadinovic,A Petric,S Stojnev,I Petkovic,D Krtinic,M Radic

DOI: https://doi.org/10.1691/ph.2024.4570

2024-10-01

Pharmazie

Abstract:Background: The incorporation of bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), has redefined therapeutic strategies for advanced ovarian cancer. This study evaluates the efficacy of bevacizumab combined with standard chemotherapy by comparing progression-free survival (PFS) and overall survival (OS) outcomes with a historical cohort of patients treated with standard chemotherapy alone. Methods: We conducted an analysis of 71 patients with advanced epithelial ovarian cancer treated at the University Clinical Center in Niš, Serbia, from April 2017 to March 2023. All patients received standard chemotherapy paired with bevacizumab and were monitored for progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier estimates. Subgroup analyses were performed based on age, ECOG performance status, presence of metastases, and pleural effusion. Additionally, a historical cohort of 30 patients treated with standard chemotherapy alone was used for comparison, and Cox regression analysis was conducted to identify factors influencing treatment outcomes. Results: The study findings indicate significant improvements in median PFS (20 months vs. 15 months) and OS (58 months vs. an undetermined upper limit) compared to the historical cohort. Subgroup analysis of the bevacizumab-treated group revealed that younger patients (<65 years) and those without metastases or pleural effusion exhibited notably better survival outcomes. The hazard ratio for PFS in patients younger than 65 was 0.65 (95% CI: 0.45-0.93), suggesting a substantial reduction in disease progression risk compared to older patients. Conclusion: Bevacizumab, when used alongside standard chemotherapy, significantly extends both PFS and OS in patients with advanced ovarian cancer. These benefits are particularly pronounced in younger patients. The results underscore the necessity of integrating bevacizumab into the treatment regimen for advanced ovarian cancer, advocating for tailored therapeutic strategies based on individual risk profiles and clinical characteristics. This study reinforces the pivotal role of bevacizumab in enhancing the current ovarian cancer treatment landscape and highlights the potential for further personalizing oncological care.
The Efficacy And Safety Of Irinotecan +/- Bevacizumab Compared With Oxaliplatin +/- Bevacizumab For Metastatic Colorectal Cancer A Meta-Analysis

Jiali Dai,Yuetong Chen,Yang Gong,Jingsun Wei,Xiaowen Cui,Hualin Yu,Wenjing Zhao,Dongying Gu,Jinfei Chen

DOI: https://doi.org/10.1097/MD.0000000000017384

IF: 1.6

2019-01-01

Medicine

Abstract:Background: Irinotecan (IRI)-based and oxaliplatin (OXA)-based regimens are available for the treatment of metastatic colorectal cancer (mCRC). Several studies have published inconsistent results in their comparisons of the efficacy and toxicity of IRI +/- bevacizumab and OXA +/- bevacizumab. This meta-analysis was performed to evaluate the efficacy and safety of these 2 regimens in patients with mCRC.Methods: We searched several databases to identify relevant studies, including PubMed, EMBASE, and the Cochrane Controlled Trials Register. The primary endpoints were overall survival (OS) and time to progression (TTP). The secondary comparisons were overall response rate (ORR) and toxicity. In addition, the hazard ratio (HR) or risk ratio (RR) values with their corresponding 95% confidence intervals (CIs) were extracted from these studies.Results: Pooled data of 13 studies demonstrated no significant differences in OS (HR= 0.96, 95% CI: 0.86-1.08, P=.53) and TTP (HR= 0.88, 95% CI: 0.72-1.08, P=.24) between the 2 groups. However, the ORR (RR= 0.87, 95% CI: 0.78-0.97, P=.02) was clearly improved in the OXA +/- bevacizumab arm. Higher incidences of grade 3/4 nausea (RR= 1.63, 95% CI: 1.28-2.07, P<.001), vomiting (RR= 1.40, 95% CI: 1.09-1.81, P=.01), diarrhea (RR= 1.44, 95% CI: 1.23-1.70, P<.001), and anemia (RR= 4.13, 95% CI: 2.75-6.22, P<.001) were observed in the IRI group. However, the incidences of grade 3/4 neutropenia (RR= 0.75, 95% CI: 0.68-0.83, P<.001), thrombocytopenia (RR= 0.43, 95% CI: 0.26-0.73, P=.002), and paresthesia/neurological disturbances (RR= 0.04, 95% CI: 0.02-0.07, P<.001) were higher in the OXA group.Conclusion: This meta-analysis confirmed that the OXA +/- bevacizumab regimen as a maintenance therapy significantly improved the ORR in patients with mCRC. Exhibiting strong efficacy and safety, the OXA and OXA plus bevacizumab regimens are preferred as first-line treatments for mCRC.
The Efficacy of Chemotherapy with Bevacizumab for Patients with Advanced Non-Small Cell Lung Cancer:Meta-Analysis from 4 Randomized Clinical Trials

Zhu Min,Zhao Naiqing

DOI: https://doi.org/10.3969/j.issn.1002-3674.2012.01.007

2012-01-01

Abstract:Objective Several randomized clinical studies have evaluated bevacizumab in combination with chemotherapy.We performed this meta analysis to better evaluate the efficacy of chemotherapy with bevacizumab for patients with advanced NSCLC.Methods We searched PubMed,Cochrane Library and abstracts from the proceedings of the American Society of Clinical Oncology(ASCO),and four randomized controlled clinical trials were identified for meta-analysis.The outcomes of efficacy included PFS and OS.Results Compared to chemotherapy alone,the hazard ratio for disease progression of bevacizumab(15 mg/kg)+chemotherapy group is 0.709(P<0.001),the hazard ratio for death 0.804(P=0.002).Conclusion For NSCLC,chemotherapy with bevacizumab will significantly improve patients' PFS and OS.
Real-World Efficacy of Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer

Jo-Ni Hung,Shih-Tien Hsu,Lou Sun,Sheau-Feng Hwang,Chih-Ku Liu,Yu-Hsiang Shih,Ming-Jer Chen,Jun-Sing Wang,Chien-Hsing Lu

DOI: https://doi.org/10.3389/fonc.2022.843278

IF: 4.7

2022-05-19

Frontiers in Oncology

Abstract:Background Bevacizumab in combination with chemotherapy prolonged the progression-free survival (PFS) of patients with recurrent epithelial ovarian cancer (EOC) in large-scale randomized controlled trials. However, real-world data for the use of bevacizumab in Asian patients with EOC is lacking. This study investigated the efficacy of adding bevacizumab to chemotherapy and compared it with that of chemotherapy alone in patients with recurrent EOC using real-world data from an Asian population. Method We conducted a retrospective cohort study using data from a tertiary medical center in central Taiwan. Patients who had EOC with first relapse between 2011 and 2019 were enrolled. Patients’ medical histories, medication treatment, and relevant information were collected. The outcomes were PFS and overall survival (OS). The Kaplan-Meier plot was used to generate a survival curve for OS and PFS. Cox proportional hazard analysis was used to determine the associations of Bevacizumab treatment with OS and PFS with adjustment of relevant variables. Subgroup analyses were conducted to determine if there was a significant variation in the aforementioned associations. Results After a median follow-up of 23 months, 67% of patients in the Bevacizumab group and 81% of patients in the non-Bevacizumab group had disease progression or death. There was no significant between-group difference in OS (p = 0.475). The median duration of PFS was 18.9 and 9.6 months, respectively, favoring those who were treated with Bevacizumab. After multivariate adjustment, treatment with Bevacizumab was associated with a lower risk of disease progression (hazard ratio 0.33, 95% CI 0.13-0.85, p = 0.021). The improvement in PFS was consistent in the subgroups of different histological types, different disease stages at diagnosis, different treatment-free intervals, those undergoing or not undergoing secondary cytoreductive surgery, diverse chemotherapy regimens. Conclusion Our findings provided crucial insights into the efficacy of bevacizumab for the treatment of recurrent EOC in the real-world setting.

oncology

[Benign monomelic amyotrophy].

Quality of Life Following Receipt of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer

Efficacy and Toxicity of Addition of Bevacizumab to Chemotherapy in Patients with Metastatic Colorectal Cancer.

Real-world study of bevacizumab treatment in patients with ovarian cancer: a Chinese single-institution study of 155 patients

On increasing the number of pulmonary alveoli in rats by postnatal treatment with retinoic acid.

Optimizing Outcomes: Bevacizumab with Carboplatin and Paclitaxel in 5110 Ovarian Cancer Patients—A Systematic Review and Meta-Analysis

Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian Cancer

Real-World Study of Neoadjuvant Chemotherapy with Bevacizumab in Patients with Ovarian Cancer: A Chinese single-institution study

Impact of Bevacizumab on Clinical Outcomes in Patients With Platinum-resistant Relapsed Ovarian Cancer

Optimizing the Treatment of Bevacizumab As First-Line Therapy for Human Epidermal Growth Factor Receptor 2 (Her2)-Negative Advanced Breast Cancer: an Updated Meta-Analysis of Published Randomized Trials

In vivo analysis reveals that the interdomain region of the yeast proliferating cell nuclear antigen is important for DNA replication and DNA repair.

The efficacy of bevacizumab combined with platinum-containing chemotherapy in the treatment of advanced non-small cell lung cancer in China: a systematic review and meta-analysis of randomized clinical trials

Efficacy and Safety of Bevacizumab and Chemotherapy in Combination with Atezolizumab in Patients with Metastatic Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials

Effectiveness and Safety of Adding Bevacizumab to Platinum-Based Chemotherapy as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis

Effect of low-dose bevacizumab on health-related quality of life in patients with recurrent high-grade glioma: A retrospective clinical study

Comparison of advanced ovarian cancer patients treated with or without bevacizumab in the US Community Oncology Clinics

Abstract B056: The unconfounded effect of bevacizumab on advanced ovarian clear cell carcinoma: a systematic review, traditional meta-analysis, and network meta-analysis

Analysis of progression-free and overall survival in ovarian cancer: Bevacizumab treatment outcomes using historical cohort

The Efficacy And Safety Of Irinotecan +/- Bevacizumab Compared With Oxaliplatin +/- Bevacizumab For Metastatic Colorectal Cancer A Meta-Analysis

The Efficacy of Chemotherapy with Bevacizumab for Patients with Advanced Non-Small Cell Lung Cancer:Meta-Analysis from 4 Randomized Clinical Trials

Real-World Efficacy of Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer